# A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs

Source: https://onco.cc/trials/nct07905183/  
OnCo record `nct07905183` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Relcobatinib run by Enliven Therapeutics, not yet recruiting.

## Summary

A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs is a phase 3 interventional study registered as NCT07905183 by Enliven Therapeutics, with 450 participants planned, started 2026-12-31. Conditions recorded: Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive and Chronic Phase Chronic Myeloid Leukemia, BCR::ABL1 Positive CML. Interventions recorded: ELVN-001 and TKI.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07905183
- Phase: 3
- Setting: A Phase 3, Multicenter, Open-Label, Randomized Study of ELVN-001 Versus Investigator-Selected Tyrosine Kinase Inhibitor (TKI) of Dasatinib, Nilotinib, or Bosutinib, in Adult Participants With Chronic Myeloid Leukemia in Chronic Phase (CP-CML), Previously Treated With One or More TKIs
- Sponsor: Enliven Therapeutics
- Enrolled: 450

## Sources

- ClinicalTrials.gov NCT07905183: https://clinicaltrials.gov/study/NCT07905183

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Chronic myeloid leukaemia (CML)](https://onco.cc/cancers/cml/)
- drugs: [Relcobatinib](https://onco.cc/drugs/relcobatinib/)
- companies: [Enliven Therapeutics](https://onco.cc/companies/enliven-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07905183.json